This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Acute lymphoblastic leukemia (ALL)	Leukemia-induced noncoding activator RNA (LUNAR1); insulin-like growth factor-1 receptor (IGF1R; CD221)	<i>In vitro</i> and mouse studies suggest depleting the LUNAR1 long noncoding RNA (lncRNA) could help treat T cell ALL (T-ALL). In T-ALL cells, shRNA against LUNAR1 repressed expression of <i>IGF1R</i> and decreased cell growth compared with control shRNA. In mice, injected T-ALL cells expressing LUNAR1 shRNA had lower proliferation than injected T-ALL cells expressing control shRNA. Next steps could include studying the effect of inhibiting LUNAR1 in additional animal models of T-ALL.	Patent and licensing status unavailable	Trimarchi, T. <i>et al. Cell</i> ; published online July 31, 2014; doi:10.1016/j.cell.2014.05.049 Contact: Iannis Aifantis, New York University School of Medicine, New York, N.Y. e-mail: iannis.aifantis@nyumc.org Contact: Aristotelis Tsirigos, same affiliation as above e-mail: aristotelis.tsirigos@nyumc.org
		SciBX 7(34); doi:10.1038/scibx.2014.1005 Published online Sept. 4, 2014		